TrovaGene, Inc. (NASDAQ:TROV)

CAPS Rating: 3 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar JaysRage (89.01) Submitted: 7/28/2015 1:26:40 PM : Outperform Start Price: $8.85 TROV Score: -26.47

Still speculative, but the investment thesis is a little stronger.

Recs

0
Member Avatar DavidLTalbot (< 20) Submitted: 6/12/2015 8:12:43 AM : Outperform Start Price: $13.49 TROV Score: -48.05

Been in since $5.89, worked out very well so far. Still a deep speculation play based on positive results for cancer mutation monitoring at several of the top cancer specialty hospitals. The key questions are:
1) Commercialization of the cancer mutation monitoring products (they have a few different ones for different cancers) which so far have been proven more effective than biopsies (urine sample versus cutting patient open, big diff) If this works out, this alone could justify a 750m market cap
2) Potentially creating and commercializing broader use urine tests like HPV (in testing) and potentially general cancer screenings for some of the hardest to detect killer cancers like pancreatic or lung cancers. This is further a-field speculation but if this part of the thesis works out it could justify a vastly higher market cap.

Like any speculative biotech play, you're either in for 10x or going to zero so not for the faint of heart.

Recs

0
Member Avatar MrMighty (69.08) Submitted: 5/15/2015 4:25:32 PM : Outperform Start Price: $10.70 TROV Score: -36.05

I think the story is pretty compelling. Diagnostic tests that use urine are way more convenient. This is coming at a time when these tests are more needed with an aging population.

Recs

0
Member Avatar ciabia (< 20) Submitted: 4/22/2015 9:23:13 PM : Outperform Start Price: $8.64 TROV Score: -23.92

non-invasive tests which have a huge market potentials. Issues with diagnostic reimbursement may cause issues, but upside seems very good.

Recs

0
Member Avatar tes1900 (< 20) Submitted: 4/22/2015 5:25:20 PM : Outperform Start Price: $8.64 TROV Score: -23.92

Everything I have read about it seem quite bullish

Recs

0
Member Avatar Aquest (57.35) Submitted: 2/18/2015 4:46:37 PM : Outperform Start Price: $5.00 TROV Score: +25.05

TROV is developing a method of detecting cancer through urinalysis. This has huge potential. Their tests will also help in determining how cancer treatments are working. All this while being non-invasive.

Recs

0
Member Avatar nancytroi (< 20) Submitted: 10/7/2013 11:40:15 AM : Outperform Start Price: $7.39 TROV Score: -35.33

New Diagnostic tests for cancer.

Recs

0
Member Avatar ctcarrigan33 (44.38) Submitted: 7/23/2013 12:14:52 PM : Outperform Start Price: $8.42 TROV Score: -44.27

Cheaper than blood tests or traditional tests, and their validation tests of the technology have been positive thus far

Results 1 - 8 of 8

Featured Broker Partners